Incidence Of Sarcopenia In Patients Research Articles

Risk Factors of Sarcopenia in COPD Patients: A Meta-Analysis.

Sarcopenia is a common complication of COPD associated with an age-related reduction in skeletal muscle mass associated with decreased muscle strength and / or reduced mobility. The incidence of sarcopenia in patients with COPD is twice that of non-COPD patients and is associated with poor prognosis, this study aimed to investigate the influencing factors of sarcopenia in COPD patients. Selected studies from PubMed, Embase, Web of Science, Cochrane Library, Wanfang, Wanfang, CNKI, CBM, and Wanfang databases as of November 12023. Patients aged 18 were selected; data were then independently extracted by two reviewers using a standard data collection form. In total, 17 articles reporting on 5408 patients were included. Age (OR = 1.083; 95% CI, 1.024-1.145), ALB (OR = 0.752; 95% CI, 0.724-0.780), BMI(OR = 0.701; 95% CI, 0.586-0.838), smoking (OR = 1.859; 95% CI, 1.037-3.334), diabetes (OR = 1.361; 95% CI, 1.095-1.692), qi deficiency (OR = 9.883; 95% CI, 2.052, 47.593), GOLD C (OR =2.232; 95% CI, 1.866, 2.670) and GOLD D (OR = 2.195; 95% CI, 1.826-2.637) were factors affecting muscle loss in COPD patients. Sarcopenia is more prevalent in patients with COPD. Age, body mass index, smoking, diabetes mellitus, qi deficiency, ALB, and GOLD grade were the contributing factors for sarcopenia in patients with chronic obstructive pulmonary disease. In the future, medical staff should not only pay attention to the early screening of sarcopenia in high-risk groups, but also provide relevant prevention information.

Sizing and mending of appendicular muscle mass for hydration during the 12-lead electrocardiogram: True incidence of sarcopenia in heart failure.

Our aim was to develop and evaluate a method for the measurement of muscle mass during the 12-channel electrocardiogram (ECG), to determine the incidence of sarcopenia in patients with overhydration and to correct it for congestion. A 12-channel ECG that simultaneously provided multifrequency segmental impedance data was used to measure total body water (TBW), extracellular water (ECW), ECW/TBW ratio and appendicular muscle mass (AppMM), validated by whole-body dual-energy X-ray absorptiometry. The mean ECW/TBW ratio was 0.24±0.018 (SD) and 0.25±0.016 for young (age range 20-25years) healthy males (n=77) and females (n=88), respectively. The deviation of the ECW/TBW ratio from this mean was used to correct AppMM for excess ECW ('dry AppMM') in 869 healthy controls and in 765 patients with chronic heart failure (CHF) New York Heart Association classes II-IV. The association of AppMM and dry AppMM with grip strength was also examined in 443 controls and patients. With increasing N-terminal pro-brain natriuretic peptide (NT-proBNP), a continuous decline of AppMM indices is observed, which is more pronounced for dry AppMM indices (for males with NT-proBNP<125pg/mL: AppMM index mean=8.4±1.05, AppMM index dry mean=8.0±1.46 [n=201, P<0.001]; for females with NT-proBNP<150pg/mL: AppMM index mean=6.4±1.0, AppMM index dry mean=5.8±1.18 [n=198, P<0.001]; for males with NT-proBNP>1000pg/mL: AppMM index mean=7.6±0.98, AppMM index dry mean=6.2±1.11 [n=137, P<0.001]; and for females with NT-proBNP>1000pg/mL: AppMM index mean=5.9±0.96, AppMM index dry mean=4.8±0.94 [n=109, P<0.001]). The correlation between AppMM and upper-body AppMM and grip strength (r-value) increased from 0.79 to 0.83 (P<0.001) and from 0.80 to 0.84 (P<0.001), respectively, after correction (n=443). The decline of AppMM with age after correction for ECW is much steeper than appreciated, especially in males: In patients with CHF and sarcopenia, the incidence of sarcopenia may be up to 30% higher after correction for ECW excess according to the European (62% vs. 57%, for males, and 43% vs. 31%, for females) and Foundation for the National Institutes of Health (FNIH) (56% vs. 46%, for males, and 54% vs. 38%, for females) consensus guidelines. The incidence of sarcopenia in CHF as defined by the European Working Group on Sarcopenia and FNIH consensus may be up to 30% higher after correction for ECW excess. This correction improves the correlation between muscle mass and strength. The presented technology will facilitate, on a large scale, screening for sarcopenia, help identify mechanisms and improve understanding of clinical outcomes.

Sarcopenia and inflammatory bowel disease: current information

With the appearance of the term "sarcopenia" and its definition, updated in 2010 and 2018, an active study of this phenomenon began. Sarcopenia is a generalized, progressive decline in skeletal muscle mass, strength, and performance leading to reduced quality of life, increased risk of falls, hospitalization, and mortality. Initially, loss of muscle mass was considered an age-associated condition. Today, there is growing interest in premature sarcopenia, which is seen in the setting of malignancy, malnutrition, and chronic inflammatory processes, including inflammatory bowel disease (IBD). Data regarding sarcopenia in patients with IBS are limited. However, published studies suggest a relationship between sarcopenia and unfavorable postoperative outcomes, need for surgical treatment, and disease activity. It is worth noting that sarcopenia is a fairly common phenomenon among patients with CKD, and is observed in 20-70% of cases. The nature of nutritional status disorders in patients suffering from CLC is undergoing changes due to the widespread epidemic of obesity. Sarcopenia in such patients may occur under the mask of obesity, remaining undiagnosed for a long time.&#x0D; The aim of the review was to analyze the current information on the incidence of sarcopenia in patients with IBS, its impact on the course of the disease and outcomes of surgical treatment. The following issues need to be addressed today: development of diagnostic criteria for the evaluation of sarcopenia in patients with ICD; inclusion of sarcopenia in the existing models of predicting surgical risks; conducting multicenter prospective studies confirming the influence of sarcopenia on the course and activity of ICD.&#x0D; Literature search containing information on relevant studies was conducted in PubMed and Google Scholar by keywords: sarcopenia, inflammatory bowel disease, nutritional status, malnutrition, ulcerative colitis, Crohn's disease.

Sarcopenia is associated with non-motor symptoms in Han Chinese patients with Parkinson's Disease: a cross-sectional study

BackgroundSarcopenia is commonly seen in the older adults and increases in incidence with age, also in Parkinson’s disease (PD). Although research has indicated that the development of sarcopenia in patients with PD may be related to both motor symptoms and non-motor symptoms (NMS), the precise relationship between the two conditions remains unclear. Therefore, we aimed to investigate the incidence of sarcopenia in patients with PD and its association with NMS.MethodsThe study included 123 patients with PD and 38 age- and sex-matched healthy controls (HC). All participants were evaluated for sarcopenia using the 2019 Asian Sarcopenia Diagnostic Criteria, and patients with PD underwent standard assessments of motor symptoms and NMS. Multiple logistic regression and receiver operating characteristic (ROC) curve analyses were used to examine the association between sarcopenia and NMS in patients with PD.ResultsThe incidence of sarcopenia was significantly higher in patients with PD than in HC (26.8% vs. 10.4%, p = 0.046). Multiple logistic regression analysis revealed that poorer sleep quality (odds ratio [OR]: 1.245; 95% confidence interval [CI]: 1.011–1.533; p = 0.040) and fatigue (OR: 1.085, 95% CI: 1.006–1.170, p = 0.034) were independently associated with sarcopenia. ROC analysis indicated that the optimal cut-off value for Pittsburgh Sleep Quality Index (PSQI) scores was 10, with 72.7% sensitivity and 74.4% specificity (area under the curve [AUC] = 0.776, 95% CI: 0.683–0.868, p < 0.001). The optimal cut-off value for Fatigue Severity Scale (FSS) scores was 39, with 87% sensitivity and 50% specificity (AUC = 0.725, 95% CI: 0.629 –0.820, p < 0.001). Joint use of FSS and PSQI scores increased the predictive value for sarcopenia(AUC = 0.804, 95% CI: 0.724–0.885, p < 0.001).ConclusionPatients with PD are more susceptible to sarcopenia than healthy older adults, and fatigue and poorer sleep are positively associated with sarcopenia. Further longitudinal studies are needed to clarify the causal relationships.

Research Progress of Traditional Chinese Medicine Formula Yiqi and Muscle Building Decoction and Carcinogenic Sarcopenia

Sarcopenia is a progressive, generalized syndrome characterized by decreased skeletal muscle content and decreased function. Patients with malignant tumors can develop sarcopenia at different stages of progression, with an incidence of 32.05%~70.40%, and the prevalence varies according to tumor type, stage, and measurement method. Compared with other types of tumors, the incidence of sarcopenia in patients with digestive tract tumors is higher, 17%~78%. In this paper, the PI3K/AKT/mTOR pathway was used to explore the mechanism of Qi Strengthening Decoction in the intervention of sarcopenia in patients with advanced esophageal cancer, in order to provide a method for the clinical treatment of sarcopenia.

Dynamic changes in the body composition during chemotherapy for gastrointestinal tumors in the context of active nutrition intervention.

To explore the dynamic changes in the body composition during chemotherapy in patients with gastrointestinal malignancies in the context of active nutrition intervention. Patients with gastrointestinal malignancies receiving first-line chemotherapy in the Department of Medical Oncology of Ordos Central Hospital from September 2019 to January 2022 were included in this study. The Nutritional Risk Screening form 2002, Patient-Generated Subjective Global Assessment form, bioelectrical impedance analysis, and dynamic changes in L3 skeletal muscle index (SMI) (L3SMI) were assessed at baseline and after chemotherapy. The recommended protocol of the Nutrition Guidelines for Cancer Patients in China 2020 was adopted as the active nutrition intervention. Chemotherapy-related toxic adverse reactions and the degree of toxicity were recorded with the adoption of the Common Terminology Criteria for Adverse Events version 4.0 by the National Institutes of Health. The type of toxicity Chemotherapy-Induced Nauseaand Vomiting(CINV) and hematological. Fifty cases were enrolled in the study, and 38 cases completed the dynamic follow-ups. The average follow-up time was 125.63d. In the context of active nutrition intervention, the prevalence of sarcopenia decreased from 26.3% before chemotherapy to 21.1% after chemotherapy. The average L3SMI decreased from 38.77 cm2/m2 to 38.04 cm2/m2, with a reduction of 1.41% ± 8.49% (P = 0.177). The SMI remained stable or increased in 57.9% (22/38) of patients. The benefit of active nutrition intervention was greater in the sarcopenic group than in the non-sarcopenic group (P = 0.033). There was an increased incidence of chemotherapy-related toxic adverse reactions of ≥ grade 3 during chemotherapy in the sarcopenic group compared with the muscle retention/gain group (P = 0.089). Active nutrition intervention might decrease the degree of reduction of L3SMI and the incidence of sarcopenia in patients with gastrointestinal tumors and raise the proportion of patients with stable or increased SMI during chemotherapy.

Scoping review of radiologic assessment and prognostic impact of skeletal muscle sarcopenia in patients undergoing endovascular repair for aortic disease

The primary objectives of our scoping review were to evaluate the methods used by research groups to assess the incidence of sarcopenia in patients with aortic disease and the extent of the evidence base that links sarcopenia to the survival of patients undergoing elective endovascular aortic repair and to identify the recurring themes or gaps in the literature to guide future research. A scoping review in accordance with the PRISMA (preferred reporting items for systematic reviews and meta-analyses) protocols extension for scoping reviews was performed. The available studies included those fully reported in English (last query, April 30, 2022). The following PICO question was used to build the search equation: "in patients with aortic disease [population] undergoing endovascular repair [intervention], what was the prevalence and prognosis of radiologically defined sarcopenia [comparison] on the short- and long-term outcomes?" A total of 31 studies were considered relevant, and 18 were included in the present scoping review. In brief, 12 studies had focused on standard endovascular aneurysm repair (EVAR), 2 on thoracic EVAR, and 4 on complex EVAR. All but two studies were retrospective in design, and only one study had included patients from a multicenter database. Sarcopenia had generally been defined using the computed tomography angiography (CTA) findings of the cross-sectional area of the psoas muscle at L3 or L4, sometimes with normalization against the height. Overall, despite the heterogeneity in the methods used for its definition, sarcopenia was highly prevalent (range, 12.5%-67.6%). The patients with sarcopenia had had higher rates of mortality (ratio ranged from 2.28 [95% confidence interval, 1.35-3.84] to 6.34 [95%confidence interval, 3.37-10.0]) and adverse events (41% vs 16%; P= .020). Sarcopenia, as identified using computed tomography angiography-based measurements of the skeletal muscle mass, was prevalent among patients undergoing elective EVAR, thoracic EVAR, or complex EVAR. The presence of sarcopenia has been shown to have a negative prognostic impact, increasing the operative risk and has been linked to poorer long-term survival.

Preoperative Assessment of Skeletal Muscle Mass and Muscle Quality Using Computed Tomography: Incidence of Sarcopenia in Patients with Intrahepatic Cholangiocarcinoma Selected for Liver Resection.

Background: Sarcopenia is considered a predictor of poor postoperative and long-term results following liver resection for intrahepatic cholangiocarcinoma (ICC). The aim of our study was to assess the incidence of sarcopenia in patients resected for ICC and its relation to preoperative clinical factors. Methods: Patients resected for ICC in our unit, with available preoperative CT scans within one month before operation, were enrolled in the study. Skeletal muscle index (SMI) and skeletal muscle radiodensity (SMD) were assessed for each patient. Results: Thirty patients matched all inclusion criteria. Low SMI values were documented in 15 patients (50.0%), and low SMD values were documented in 10 patients (33.3%). SMI was significantly greater in males (p < 0.001). In patients who were underweight, the incidence of low SMI was significantly higher than that of high SMI (p = 0.031). In patients who were overweight/obese, the incidence of high SMI was significantly higher than that of low SMI (p = 0.003) and the incidence of low SMD was significantly higher than that of high SMD (p = 0.038). In the univariate analysis, no preoperative factors (clinical and tumor-related factors), in particular BMI, were found to be independent predictors of low SMI. Conclusions: The incidence of sarcopenia was 50.0% in patients selected for liver resection for ICC and was not related to the preoperative clinical factors. A multidisciplinary evaluation of the nutritional status is fundamental before liver resection in patients.

Evaluating Sarcopenia by Using the Bioelectrical Impedance Analysis in Patients with Acute Myeloid Leukemia After Chemotherapy.

BackgroundWe aimed to explore the potential association of body composition parameters measured by bioelectrical impedance analysis (BIA) with the incidence of sarcopenia in patients with acute myeloid leukemia (AML) (non-M3) after chemotherapy.Patients and MethodsThis was a single-center observational study. Sixty-nine patients with newly diagnosed AML underwent BIA at the time of initial diagnosis and after completion of three chemotherapy sessions. Pre- and post-chemotherapy BIA parameters were compared. Sarcopenia was defined as low skeletal muscle mass plus low muscle strength according to the Asian Working Group for Sarcopenia (AWGS). Association of sarcopenia with mid-arm muscle circumference (MAMC) and intracellular water (ICW) was assessed by multivariate logistic regression.ResultsThere was a significant increase in the prevalence of sarcopenia after chemotherapy (39.1% vs 14.5%, P<0.001). Skeletal muscle mass (SMM), fat-free mass (FFM), and soft lean mass (SLM) showed a significant decrease after chemotherapy (P<0.05). MAMC, ICW, and total body water (TBW) significantly decreased after chemotherapy (P<0.05). BIA indices including appendicular skeletal muscle mass (ASM) (r=0.889, P<0.001), ICW (r=0.869, P<0.001), MAMC (r=0.849, P<0.001) showed a positive correlation with SMI. Moreover, ASM (r=−0.453 P=0.001), ICW (r=−0.322, P<0.05), and MAMC (r=−0.352, P<0.05) showed a negative correlation with sarcopenia. On multivariate logistic regression analysis, increased ICW was associated with decreased risk of sarcopenia [odds ratio (OR): 0.50; 95% confidence interval (CI) 0.30–0.82]. Each additional unit of MAMC after chemotherapy was associated with 71% lower risk of sarcopenia (OR: 0.29; 95% CI 0.13–0.66).ConclusionThe incidence of sarcopenia was associated with chemotherapy of patients with AML (non-M3) as reflected by body composition changes.

The Relationship between the Mechanism of Sarcopenia and Exercise Based on Data Mining.

Due to the increasing prosperity of human life science and technology, many huge research results have been obtained, and the scientific research of molecular biology is developing rapidly. Therefore, the output of biological genome data has increased exponentially, which constitutes a huge amount of data analysis. The seemingly chaotic and massive amount of data information actually contains a large amount of data and information of great key scientific significance and value. Therefore, this kind of genomic data information not only contains the information content that describes the characteristics of human life but also contains the information content that can express the essence of the biological organism. It includes macroeconomic information that can reflect the basic structure and capabilities of living organisms and microinformation in related fields of molecular biology. This massive amount of genetic data is usually closely related to each other, can influence each other, and does not exist alone. In the article, the causes of uncertain data and the classification of uncertain data are introduced, and the basic concepts and related algorithms of data mining are explained. Focusing on the research and analysis of abnormal point detection and clustering algorithms in uncertain data mining technology, this paper solves the problem of how to obtain more diverse and accurate outlier detection and cluster analysis results in uncertain data. The results showed that whether it was related to obesity or not, the Lp(a) level of the sarcopenia group was significantly higher than that of the nonsarcopenia group. At the same time, the correlation analysis showed that ASM/height was negatively correlated with Lp(a). ASM/height is one of the criteria for diagnosing sarcoidosis, and it is also the core of the analysis. Among the 1956 tumor patients collected in this study, 432 had sarcopenia, accounting for 22.08%, and the incidence of sarcopenia in patients with gastrointestinal tumors increased.

Abstract 12968: Impact of Loop Diuretics Use on Skeletal Muscle Depletion Among Patients Being Evaluated for Known or Suspected Coronary Artery Disease a Propensity Score Matching Analysis

Background: It is well known that sarcopenia worsens the prognosis among patients with heart failure (HF). Causes and incidence of sarcopenia in patients with HF have become more important because of the increasing number of elderly HF patients worldwide. Although previous basic research suggested that loop diuretics can lead skeletal muscle depletion, the relationship has not been clarified in the clinical settings. The purpose of this study is to investigate the relationship between skeletal muscle loss and use of loop diuretics in patients with HF. Methods: We retrospectively evaluated 178 patients being evaluated for known or suspected coronary artery disease with cardiac catheterization from January 2010 to January 2019 and receiving abdominal computed tomography (CT) both baseline and at follow-up (mean 522 days).The skeletal muscle cross-sectional area was measured using CT scan at the level of third vertebra and total volume of the skeletal muscle cross-sectional area with five slices every 1mm apart was evaluated. Impact of loop-diuretics use on skeletal muscle depletion and overall survival was evaluated using 1:1 propensity score (PS) matching analysis. Results: A total of fifty-eight patients were evaluated (twenty-nine patients in both loop-diuretics use group and non-loop group) after 1:1 PS matching. The median absolute muscle-loss volume was significantly larger in loop diuretics use group (714 cm 2 ) compared to non-loop group (73.3cm 2 ). (p=0.026) Univariable analysis revealed that duration-adjusted skeletal muscle depletion volume was significantly associated with loop diuretic use (Δ=480cm 2 /year: 95% confidence interval, 64.1-897: p=0.024). Median overall survival was 796 days in the loop-diuretics use group and 865 days in the non-loop diuretics group (hazard ratio 0·99, 95% CI 0·35-2.75; p=0.979). Conclusion: Our study suggested that the use of loop diuretics can be related with skeletal muscle loss among patients being evaluated for known or suspected coronary artery disease.

An incidence of sarcopenia in patients with stable chronic obstructive pulmonary disease: a comparison of diagnostic algorithms of European Working Group on Sarcopenia in Older People, 2018 versus 2010

The first aim of this study was to compare an incidence of sarcopenia in patients with chronic obstructive pulmonary disease (COPD) when using updated (2018) the European Working Group on Sarcopenia in Older People (EWGSOP) algorithm compared to the previous version (2010). The second aim was to determine relationships between clinical and functional parameters of COPD and parameters of sarcopenia. Methods . The study involved 86 stable COPD patients (68 males; mean age, 66.6 ± 8.7 years). The diagnosis of COPD was made according to GINA 2019. Sarcopenia was diagnosed according to EWGSOP guidelines 2010 and 2018. Muscle mass was assessed using dual-energy Xray absorptiometry (DXA). Results . Walking speed was measured in all patients according to EWGSOP guideline 2010. Additionally, hand muscle strength was measured in patients with walking speed > 0.8 m/s (n = 25). DXA was required to 72% of patients to confirm the diagnosis of sarcopenia. Sarcopenia was defined in 38 (44.1%) patients including severe sarcopenia in 20 (23.3%). According to results of SARC-F questionnaire, further hand muscle strength measurement was required to 64 patients and DXA was required to 51 (59.3%) patients. As a result, sarcopenia was confirmed in 38 (44.1%) patients including severe sarcopenia in 34 (39.5%) patients. The incidence of sarcopenia was higher in patients with more severe symptoms of COPD and more severe bronchial obstruction ( р = 0.001), and in patients with emphysema ( р < 0.03). Conclusion . The incidence of sarcopenia in COPD patients did not differ when used different diagnostic algorithms (EWGSOP, 2010 vs 2018) and was 44.1%. The need in additional tests, including expensive tests, was lower and the incidence of sarcopenia was higher (39.5% vs 23.3%) following the EWGSOP algorithm, 2018, compared to that of 2010. The incidence of sarcopenia increased in more severe COPD, in patients with emphysema, severe clinical symptoms, severe and very severe bronchial obstruction. The incidence of sarcopenia was not related to the patient’s age.

The relation between sarcopenia, associated factors, and disease activity in patients with rheumatoid arthritis

Aim The aim of this study was to detect the incidence of sarcopenia in patients with rheumatoid arthritis (RA) and study associated factors. Patients and methods Dual-energy X-ray absorptiometry was used to assess the body composition of 80 patients with RA and 80 healthy controls. Sarcopenia was defined as a relative skeletal muscle index of less than 5.5 kg/m2 in male and less than 7.26 kg/m2 in female patients. BMI, waist circumference, and disease activity score 28 erythrocyte sedimentation rate were used to assess disease activity. Functional disability was measured using Health Assessment Questionnaire, and 4-m gait speed test was used to determine patient's physical performance. Results The relative skeletal muscle index was significantly lower in the RA group (6.1 ± 1.2 vs. 7.2 ± 0.9 kg/m2, P Conclusion Sarcopenia is a common finding in patients with RA but does not have an association with disease activity, functional disability, or physical performance. Future studies are required for better comprehension of sarcopenia to clear up its relationship with different comorbidities.

Prognostic Indication of Sarcopenia for Wound Complication After Total Laryngectomy

<h3>Importance</h3> Postoperative wound complications after total laryngectomy (TL) increase hospital stay, costs, and delay adjuvant therapy when indicated. Recently, sarcopenia has been identified as a predictor of postoperative complications in patients undergoing major surgery but has not been assessed in head and neck surgery patients. <h3>Objective</h3> To determine the incidence of sarcopenia in patients with squamous cell carcinoma (SCC) undergoing TL and evaluate its association with the development of postoperative wound complications. <h3>Design, Setting, and Participants</h3> Retrospective medical chart review of 70 patients with SCC who underwent TL with cross-sectional abdominal imaging obtained preoperatively from 2004 to 2016 in a tertiary care hospital. Patients were determined to have sarcopenia present if the skeletal muscle index was calculated to be less than 38.5 cm²/m²for women and 52.4 cm²/m²for men. Demographic data included age, sex, smoking history, Charlson Comorbidity Index (CCI) score, prior radiation history, tumor stage, body mass index (BMI), and preoperative albumin levels. <h3>Main Outcomes and Measures</h3> Measurements of abdominal wall and paraspinal musculature at the cross-sectional L3 vertebral body were performed, normalized for height, and compared with previously defined sex-specific cutoff values to identify sarcopenia. Postoperative complications including all complications, wound-related complications, and pharyngo-cutaneous fistula (PCF) were determined. <h3>Results</h3> Sarcopenia was identified preoperatively in 54 (77%) patients. There was not a significant difference between the sarcopenia group and the nonsarcopenia group for any data except BMI (Cohen<i>d</i> = 1; 95% CI, 0.41-1.57) and preoperative albumin levels (Cohen<i>d</i> = 0.69; 95% CI, 0.11-1.25). Of 70 patients, 13 (24%) in the sarcopenia group developed a PCF compared with 0 (0%) without sarcopenia (OR, 1.32; 95% CI, 1.13-1.53). Similarly, 35 (50%) patients in the sarcopenia group developed a wound complication compared with 2 (13%) in the nonsarcopenia group (OR, 7.54; 95% CI, 1.56-36.4). On univariate analysis, sarcopenia was the only predictive factor of any complication (OR, 6.53; 95% CI, 1.84-23.23) and any wound complication (OR, 7.54; 95% CI, 1.56-36.4). On multivariable analysis of preoperative albumin levels and preoperative sarcopenia, only sarcopenia was a significant predictor for all complications (OR, 7.96; 95% CI, 1.39-45.29). <h3>Conclusions and Relevance</h3> Sarcopenia is an independent negative prognostic indicator for the development of all complications and wound complications after TL for the treatment of SCC.

Sarcopenia in patients undergoing maintenance hemodialysis: incidence rate, risk factors and its effect on survival risk

Background Sarcopenia is a degenerative syndrome mainly characterized by the atrophy of skeletal muscle, along with the decrease of muscle strength and function. However, there are currently few studies concerning sarcopenia in patients undergoing maintenance hemodialysis dialysis (MHD). This study was aimed to investigate the incidence of sarcopenia in MHD patients and its influencing factors, as well as its impact on survival risk. Method All 131 MHD patients enrolled in our study were tested with bioelectrical impedance analysis (BIA) and grip strength. Demographic data was collected and anthropometric measurement and laboratory examination were conducted. Results The total incidence of sarcopenia within the 131 MHD patients was 13.7% and the incidence of sarcopenia in patients over 60 years was 33.3%. The dialysis duration, with or without diabetes, serum phosphorus and pre-albumin levels of sarcopenic patients were significantly different from those of non-sarcopenicones; the modified quantitative subjective global assessment (MQSGA) scores of sarcopenic patients were higher than those without sarcopenia. Multivariate analysis showed that dialysis duration, diabetes and serum phosphorus level were independent risk factors for sarcopenia in MHD patients. Kaplan–Meier survival analysis showed a one-year survival of 88.9% in sarcopenic patients, which was significantly lower than non-sarcopenic patients. Conclusion The incidence of sarcopenia in MHD patients was high and increased gradually with age. Dialysis duration, diabetes, serum phosphorus level and malnutrition predisposed the patients to sarcopenia. One-year follow-up found that the mortality risk of sarcopenic patients was higher than that of non-sarcopenic patients.